This site is intended for healthcare professionals

FDA accepts BLA resubmission for eflapegrastim to treat febrile neutropenia.

Read time: 1 mins
Published:12th Apr 2022

Spectrum Pharmaceuticals announced that the resubmitted Biologics License Application (BLA) for eflapegrastim has been accepted for filing.

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of September 9, 2022. Spectrum is seeking an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Condition: Neutropenia
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.